Natco Pharma launches Brivaracetam tablets in India

26 Feb 2021 Evaluate

Natco Pharma has launched Brivaracetam tablets under brand Brecita in India. Brivaracetam is indicated towards treatment of epilepsy. Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under brand name Briviact. Natco’s Brecita tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of Rs 25 and Rs 35 per tablet respectively.

Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

933.60 -15.25 (-1.61%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×